Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Tips from these results
Recent Share tips:
- Sell Powerhouse Energy Group (PHE) by Tom Winnifrith in ShareProphets
- Buy Residential Secure Income (RESI) by Royston Wild in The Motley Fool
- Hold Netcall (NET) by Kevin Godbold in The Motley Fool
- Buy IntegraFin Holding (IHP) by Jabran Khan in The Motley Fool
- Avoid Physiomics (PYC) by Steve Moore in ShareProphets
- Buy Greencoat UK Wind (UKW) by Yasmin Rufo in The Motley Fool
- Strong Buy Lloyds Banking Group (LLOY) by Alan Oscroft in The Motley Fool
- Buy Hiscox Limited (DI) (HSX) by Jon Smith in The Motley Fool
- Buy Phoenix Group Holdings (PHNX) by Bank of America
- Underperform Quilter (QLT) by Bank of America
- Neutral St James's Place (STJ) by Bank of America
- Buy Old Mutual Limited NPV (DI) (OMU) by Bank of America
- Buy M&G (MNG) by Bank of America
- Buy Hargreaves Lansdown (HL.) by Bank of America
- Buy Legal & General Group (LGEN) by Bank of America
- Underperform Admiral Group (ADM) by Bank of America
- Neutral Aviva (AV.) by Bank of America
- Underperform Direct Line Insurance Group (DLG) by Bank of America
- Buy Prudential (PRU) by Bank of America
- Neutral Auto Trader Group (AUTO) by Goldman Sachs
Immupharma (IMM)
Health Care Sector
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
Immupharma Overview
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.Latest Immupharma Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | Northland Capital | – | 2018-04-17 16:35:00 17/04/2018 | – |
| – | Paul Summers | – | 2018-03-01 09:50:00 01/03/2018 | – |
| – | FinnCap | – | 2017-12-21 11:30:00 21/12/2017 | – |
| – | FinnCap | – | 2017-12-12 08:00:00 12/12/2017 | – |
| – | Harvey Jones | – | 2017-10-09 15:30:00 09/10/2017 | – |
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
Immupharma Overview
ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor is the company's most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.Latest Immupharma Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | Northland Capital | – | 2018-04-17 16:35:00 17/04/2018 | – |
| – | Paul Summers | – | 2018-03-01 09:50:00 01/03/2018 | – |
| – | FinnCap | – | 2017-12-21 11:30:00 21/12/2017 | – |
| – | FinnCap | – | 2017-12-12 08:00:00 12/12/2017 | – |
| – | Harvey Jones | – | 2017-10-09 15:30:00 09/10/2017 | – |